Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

RCT (n=1471, Canada & India) found that in patients with AF or mechanical heart valves who had warfarin interrupted for a procedure, no significant benefit was found for postop dalteparin bridging to prevent major thromboembolism (occurred in 1.0% vs. 1.2% placebo within 90 days)

Source:

British Medical Journal